## Jason Trubiano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4842821/publications.pdf

Version: 2024-02-01

163 papers 4,404 citations

126708 33 h-index 59 g-index

168 all docs 168
docs citations

168 times ranked 4677 citing authors

#	Article	IF	Citations
1	Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context. Internal Medicine Journal, 2023, 53, 74-83.	0.5	7
2	Long-term outcomes of an electronic medical record (EMR)–integrated antimicrobial stewardship (AMS) intensive care unit (ICU) ward round. Infection Control and Hospital Epidemiology, 2022, 43, 670-672.	1.0	0
3	Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Annals of Allergy, Asthma and Immunology, 2022, 128, 27-32.	0.5	17
4	<scp>ESCAPEâ€Allergy</scp> : Evaluating screening for children and adolescents with penicillin allergy. Journal of Paediatrics and Child Health, 2022, 58, 83-89.	0.4	2
5	Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1038-1042.	2.7	9
6	Are NKT cells a useful predictor of COVID-19 severity?. Immunity, 2022, 55, 185-187.	6.6	9
7	New Clinical Insights Into Pediatric DRESS to Tailor Future Care?. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 275-276.	2.0	1
8	Blister fluid as a cellular input for exÂvivo diagnostics in drug-induced severe cutaneous adverse reactions improves sensitivity and explores immunopathogenesis., 2022, 1, 16-21.		6
9	Anaphylaxis in Victoria: presentations to emergency departments, with a focus on drug―and antimicrobial―elated cases. Medical Journal of Australia, 2022, , .	0.8	3
10	A Risk-Based Approach to Penicillin Allergy. Immunology and Allergy Clinics of North America, 2022, 42, 375-389.	0.7	4
11	The assessment of severe cutaneous adverse drug reactions. Australian Prescriber, 2022, 45, 43-48.	0.5	7
12	Standards for practical intravenous rapid drug desensitization & Lamp; delabeling: A WAO committee statement. World Allergy Organization Journal, 2022, 15, 100640.	1.6	18
13	The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. Clinical Infectious Diseases, 2021, 73, 487-496.	2.9	74
14	Cross-reactivity between vancomycin, teicoplanin, and telavancin in patientsÂwith HLA-Aâ^—32:01–positive vancomycin-induced DRESS sharing an HLA class II haplotype. Journal of Allergy and Clinical Immunology, 2021, 147, 403-405.	1.5	26
15	The impact of antibiotic allergy testing in transplant patients. Transplant Infectious Disease, 2021, 23, e13411.	0.7	4
16	A Survey on Knowledge Gaps in Assessment and Management of Severe Drug Hypersensitivity Reactions: Multicenter Crossâ€Sectional Study of Australian Health Care Providers. Journal of Clinical Pharmacology, 2021, 61, 25-31.	1.0	3
17	Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 435-444.e13.	2.0	20
18	Letter to the Editor: Evolving evidence for immunosuppressants in COVID-19. Australian Prescriber, 2021, 44, 7.	0.5	0

#	Article	IF	CITATIONS
19	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	3.3	115
20	The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapyâ€"A Prospective Longitudinal Study. Frontiers in Immunology, 2021, 12, 646095.	2.2	13
21	A pilot doubleâ€blind safety and feasibility randomized controlled trial of highâ€dose intravenous zinc in hospitalized COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 3261-3267.	2.5	43
22	Evolution of the Human Cytokine Response from Acute Illness to Disease Resolution in SARS-Cov-2 Infectionâ€"Implications for Therapeutic Monitoring and Therapeutic Targets. Journal of Clinical Immunology, 2021, 41, 1162-1164.	2.0	2
23	Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study. The Lancet Regional Health - Western Pacific, 2021, 9, 100115.	1.3	29
24	The Role of InÂVivo and ExÂVivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2010-2015.e4.	2.0	26
25	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	6.6	106
26	Risk factors for readmission following inpatient management of <scp>COVID</scp> â€19 in a lowâ€prevalence setting. Internal Medicine Journal, 2021, 51, 821-823.	0.5	7
27	Identifying patterns in unplanned hospital admissions during the <scp>COVID</scp> â€19 pandemic: a singleâ€centre retrospective study. Internal Medicine Journal, 2021, 51, 868-872.	0.5	2
28	Delayed hypersensitivity reactions to piperacillin-tazobactam. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2548.	2.0	2
29	Staff to staff transmission as a driver of healthcare worker infections with COVID-19. Infection, Disease and Health, 2021, 26, 276-283.	0.5	24
30	Treating Through Drug-Associated Exanthems in Drug Allergy Management: Current Evidence and Clinical Aspects. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2984-2993.	2.0	9
31	Dose Dependent Antimicrobial Cellular Cytotoxicityâ€"Implications for ex vivo Diagnostics. Frontiers in Pharmacology, 2021, 12, 640012.	1.6	6
32	Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication. Open Forum Infectious Diseases, 2021, 8, ofab359.	0.4	5
33	Considerations for cross-reactivity between vancomycin and other glycopeptides. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3233.	2.0	2
34	New Pathways to Navigate an Old Problem of Tuberculosis Therapy-Associated Adverse Drug Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3450-3451.	2.0	0
35	A Cryptic Clot. Clinical Infectious Diseases, 2021, 73, 940-943.	2.9	0
36	Antimicrobial stewardship in Australia: the role of qualitative research in programme development. JAC-Antimicrobial Resistance, 2021, 3, dlab166.	0.9	8

#	Article	IF	CITATIONS
37	Antifungal hypersensitivity reactions and cross-reactivity patterns. Current Opinion in Infectious Diseases, 2021, Publish Ahead of Print, 559-572.	1.3	O
38	The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3847-3849.	2.0	9
39	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Internal Medicine Journal, 2021, 51, 37-66.	0.5	24
40	The challenge of de″abeling penicillin allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 273-288.	2.7	136
41	Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1142-1146.e4.	2.0	22
42	Cryptococcal infection in patients with haematological and solid organ malignancy in the era of targeted and immune-based therapies. Clinical Microbiology and Infection, 2020, 26, 519-521.	2.8	6
43	Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia. Supportive Care in Cancer, 2020, 28, 4337-4343.	1.0	4
44	Analysis of Skin-Resident Memory T Cells Following Drug Hypersensitivity Reactions. Journal of Investigative Dermatology, 2020, 140, 1442-1445.e4.	0.3	19
45	An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 847.	0.7	6
46	Matched Case-Control Study of the Long-Term Impact of Beta-Lactam Antibiotic Allergy Testing. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
47	Patient perspectives on antibiotic allergy delabeling: Enablers and barriers. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3637-3639.e5.	2.0	6
48	Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2878-2895.e6.	2.0	27
49	COVID â€19: collaboration will keep us ahead of the curve. Internal Medicine Journal, 2020, 50, 784-786.	0.5	2
50	The democratization of de-labeling: a review of direct oral challenge in adults with low-risk penicillin allergy. Expert Review of Anti-Infective Therapy, 2020, 18, 1143-1153.	2.0	16
51	Time to Acute Kidney Injury in $\hat{I}^2$ -Lactamâ $\hat{I}^3$ Induced Acute Interstitial Nephritis. Kidney International Reports, 2020, 5, 1068-1070.	0.4	9
52	Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol. BMJ Open, 2020, 10, e040580.	0.8	26
53	Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection. Pathology, 2020, 52, 778-782.	0.3	14
54	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. Journal of Allergy and Clinical Immunology, 2020, 146, 518-534.e1.	1.5	180

#	Article	IF	CITATIONS
55	An infectious diseases perspective on the microbiome and allogeneic stem cell transplant. Current Opinion in Infectious Diseases, 2020, 33, 426-432.	1.3	O
56	Delayed hypersensitivity associated with amoxicillinâ€clavulanate. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2700-2702.	2.7	7
57	Children with reported penicillin allergy. Annals of Allergy, Asthma and Immunology, 2020, 124, 558-565.	0.5	42
58	Alterations in Smell or Tasteâ€"Classic Coronavirus Disease 2019?. Clinical Infectious Diseases, 2020, 71, 2307-2309.	2.9	16
59	Burden of antibiotic allergy labels in Australian aged care residents: Findings from a national point-prevalence survey. Infection Control and Hospital Epidemiology, 2020, 41, 641-644.	1.0	2
60	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.0	41
61	Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine, 2020, 180, 745.	2.6	135
62	Adverse reactions to vancomycin and cross-reactivity with other antibiotics. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 352-361.	1.1	14
63	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. Frontiers in Pharmacology, 2020, 11, 573573.	1.6	32
64	Ventilation perfusion lung SPECT / CT in pregnancy during COVID â€19. Internal Medicine Journal, 2020, 50, 1588-1590.	0.5	5
65	COVID-MATCH65â€"A prospectively derived clinical decision rule for severe acute respiratory syndrome coronavirus 2. PLoS ONE, 2020, 15, e0243414.	1.1	11
66	Editorial: Immunosuppression for COVID-19: repurposing medicines in a pandemic. Australian Prescriber, 2020, 43, 106-107.	0.5	5
67	Treatment of <i>Neisseria meningitidis</i> prosthetic joint infections with short-course antibiotics: three cases and a literature review. Journal of Bone and Joint Infection, 2020, 6, 33-37.	0.6	0
68	Counting the cost of critical antibiotic shortages. Journal of Antimicrobial Chemotherapy, 2019, 74, 273-275.	1.3	3
69	Outcomes of an electronic medical record (EMR)–driven intensive care unit (ICU)-antimicrobial stewardship (AMS) ward round: Assessing the "Five Moments of Antimicrobial Prescribing― Infection Control and Hospital Epidemiology, 2019, 40, 1170-1175.	1.0	12
70	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Molecular Diagnostics, 2019, 21, 782-789.	1.2	12
71	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2095-2096.	2.0	0
72	Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2151-2153.	2.0	22

#	Article	IF	Citations
73	High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing. Leukemia and Lymphoma, 2019, 60, 3455-3460.	0.6	4
74	Long-term impacts of antibiotic allergy testing on patient perceptions and antibiotic utilization. JAC-Antimicrobial Resistance, 2019, 1, dlz058.	0.9	5
75	Antimicrobial anaphylaxis: the changing face of severe antimicrobial allergy. Journal of Antimicrobial Chemotherapy, 2019, 75, 229-235.	1.3	7
76	The Global Implications of the Gentamicin Histamine Contamination: Sorting Fact from Fiction. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	2
77	Immunosuppressed Returned Traveler With Ulcerating Skin Lesion and Fever. Clinical Infectious Diseases, 2019, 68, 1747-1749.	2.9	1
78	Evaluation of a pharmacist-led penicillin allergy de-labelling ward round: a novel antimicrobial stewardship intervention. Journal of Antimicrobial Chemotherapy, 2019, 74, 1725-1730.	1.3	64
79	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology, 2019, 144, 183-192.	1.5	118
80	Bartonella Quintanaprosthetic aortitis successfully treated with doxycycline. BMJ Case Reports, 2019, 12, e229877.	0.2	1
81	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2854-2856.	2.0	0
82	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	1.5	144
83	Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 228-230.	2.0	3
84	The safety of antibiotic skin testing in severe T-cell–mediated hypersensitivity of immunocompetent and immunocompromised hosts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1341-1343.e1.	2.0	25
85	Antibiotic allergy labels in hospitalized and critically ill adults: A review of current impacts of inaccurate labelling. British Journal of Clinical Pharmacology, 2019, 85, 492-500.	1.1	21
86	Antibiotic allergy. Lancet, The, 2019, 393, 183-198.	6.3	358
87	Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1063-1065.e5.	2.0	65
88	Penicillin allergy: a practical approach to assessment and prescribing. Australian Prescriber, 2019, 42, 192-199.	0.5	25
89	Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions. , 2019, , 275-282.		0
90	The burden of antibiotic allergies in adults in an Australian intensive care unit: the BASIS study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 265-73.	0.0	2

#	Article	IF	Citations
91	Single Cell Approaches to Define the Pathogenic Immune Cells that Mediate Drug Hypersensitivity. Journal of Allergy and Clinical Immunology, 2018, 141, AB88.	1.5	0
92	The Combined Utility of ExÂVivo IFN-Î <sup>3</sup> Release Enzyme-Linked ImmunoSpot Assay and InÂVivo SkinÂTesting in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1287-1296.e1.	2.0	47
93	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	2.0	134
94	Drugâ€induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. Internal Medicine Journal, 2018, 48, 549-555.	0.5	13
95	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
96	Taking the challenge: A protocolized approach to optimize Pneumocystis pneumonia prophylaxis in renal transplant recipients. American Journal of Transplantation, 2018, 18, 462-466.	2.6	25
97	1787. The Safety and Efficacy of an Oral Penicillin Rechallenge Program in Cancer Patients: A Pilot Multicenter Study. Open Forum Infectious Diseases, 2018, 5, S506-S506.	0.4	1
98	1578. Back to Bactrim–Utilizing Preferred Prophylaxis Strategies in Immunocompromised Hosts Via a Trimethoprim-Sulfamethoxazole Rechallenge Program. Open Forum Infectious Diseases, 2018, 5, S493-S493.	0.4	1
99	The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. Open Forum Infectious Diseases, 2018, 5, ofy306.	0.4	57
100	Review of epiglottitis in the post <i>Haemophilus influenzae</i> typeâ€b vaccine era. ANZ Journal of Surgery, 2018, 88, 1135-1140.	0.3	15
101	Beyond Penicillin: Rapid Desensitization for Specific Flucloxacillin Hypersensitivity. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	2
102	How antibiotic allergy labels may be harming our most vulnerable patients. Medical Journal of Australia, 2018, 208, 469-470.	0.8	15
103	Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. Journal of Antimicrobial Chemotherapy, 2018, 73, 3209-3211.	1.3	6
104	Medicationâ€related anaphylaxis treated in hospital: Agents implicated, patient outcomes, and management lessons. Pharmacoepidemiology and Drug Safety, 2018, 27, 1029-1033.	0.9	6
105	Fulminant meningococcal sepsis due to nonâ€groupable Neisseria meningitidis in a patient receiving eculizumab. Medical Journal of Australia, 2018, 208, 478-479.	0.8	3
106	Dapsone safety in hematology patients: Pathways to optimizing <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in hematology malignancy and transplant recipients. Transplant Infectious Disease, 2018, 20, e12968.	0.7	10
107	Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting. Journal of Clinical Pharmacology, 2018, 58, 1332-1339.	1.0	15
108	The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia – Remains similar despite changing geographic distribution of disease. PLoS Neglected Tropical Diseases, 2018, 12, e0006323.	1.3	34

#	Article	IF	Citations
109	Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study. Supportive Care in Cancer, 2017, 25, 1923-1930.	1.0	22
110	Recent advances in the understanding of severe cutaneous adverse reactions. British Journal of Dermatology, 2017, 177, 1234-1247.	1.4	27
111	Antibiotic Allergy Labels in a Liver Transplant Recipient Study. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	20
112	Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 823-826.	2.0	13
113	Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. Clinical Infectious Diseases, 2017, 65, 166-174.	2.9	106
114	The Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicentre Evaluation. Journal of Allergy and Clinical Immunology, 2017, 139, AB377.	1.5	1
115	Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia and Lymphoma, 2017, 58, 2379-2386.	0.6	21
116	The 3 Cs of Antibiotic Allergyâ€"Classification, Cross-Reactivity, and Collaboration. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1532-1542.	2.0	60
117	Ibrutinib may impair serological responses to influenza vaccination. Haematologica, 2017, 102, e397-e399.	1.7	79
118	Short Communication: <i>Mycobacterium avium</i> Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2017, 33, 1202-1204.	0.5	8
119	Persistence of Penicillin Allergyâ€"Reply. JAMA - Journal of the American Medical Association, 2017, 318, 1714.	3.8	4
120	Penicillin Allergy Is Not Necessarily Forever. JAMA - Journal of the American Medical Association, 2017, 318, 82.	3.8	139
121	Poor reporting and documentation in drugâ€associated Stevensâ€Johnson Syndrome and Toxic Epidermal Necrolysis – Lessons for medication safety. British Journal of Clinical Pharmacology, 2017, 83, 224-226.	1.1	5
122	Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. Open Forum Infectious Diseases, 2016, 3, ofw153.	0.4	57
123	Old but not forgotten: Antibiotic allergies in General Medicine (the AGM Study). Medical Journal of Australia, 2016, 204, 273-273.	0.8	39
124	More than skin deep. Ten year followâ€up of delayed cutaneous adverse drug reactions (CADR). British Journal of Clinical Pharmacology, 2016, 82, 1040-1047.	1.1	10
125	Mucormycete infection or colonisation: experience of an Australian tertiary referral centre. Mycoses, 2016, 59, 291-295.	1.8	8
126	The revolving door: antibiotic allergy labelling in a tertiary care centre. Internal Medicine Journal, 2016, 46, 1276-1283.	0.5	52

#	Article	IF	Citations
127	Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes. International Journal of Antimicrobial Agents, 2016, 47, 391-396.	1.1	7
128	The epidemiology of <i>Clostridium difficile </i> infection in patients with cancer. Expert Review of Anti-Infective Therapy, 2016, 14, 1077-1085.	2.0	19
129	Yeast Infections After Haematopoietic Stem Cell Transplantation. , 2016, , 677-691.		0
130	Australasian Society of Infectious Diseases updated guidelines for the management of <i>Clostridium difficile</i> infection in adults and children in Australia and New Zealand. Internal Medicine Journal, 2016, 46, 479-493.	0.5	88
131	Return to sender: the need to reâ€address patient antibiotic allergy labels in Australia and New Zealand. Internal Medicine Journal, 2016, 46, 1311-1317.	0.5	22
132	Travel vaccination recommendations and endemic infection risks in solid organ transplantation recipients. Journal of Travel Medicine, 2016, 23, taw058.	1.4	20
133	Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. Current Opinion in Infectious Diseases, 2016, 29, 561-576.	1.3	15
134	Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudoâ€obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion. Internal Medicine Journal, 2016, 46, 238-239.	0.5	8
135	AGM– Antibiotic Allergies in General Medicine. Journal of Allergy and Clinical Immunology, 2016, 137, AB257.	1.5	O
136	Antibiotic Allergy De-Labeling: Teaching an Old Dog New Tricks. Journal of Allergy and Clinical Immunology, 2016, 137, AB398.	1.5	2
137	A Comparative Analysis Between Antibiotic- and Nonantibiotic-Associated Delayed Cutaneous Adverse Drug Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1187-1193.	2.0	35
138	Clinical utility of panfungal polymerase chain reaction for the diagnosis of invasive fungal disease: a single center experience. Medical Mycology, 2016, 54, 138-146.	0.3	36
139	Antimicrobial allergy â€`labels' drive inappropriate antimicrobial prescribing: lessons for stewardship. Journal of Antimicrobial Chemotherapy, 2016, 71, 1715-1722.	1.3	95
140	The prevalence and impact of antimicrobial allergies and adverse drug reactions at an Australian tertiary centre. BMC Infectious Diseases, 2015, 15, 572.	1.3	53
141	The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients. Antimicrobial Resistance and Infection Control, 2015, 4, 23.	1.5	52
142	Testicular loss following bacterial epididymo-orchitis: Case report and literature review. Canadian Urological Association Journal, 2015, 9, 148.	0.3	20
143	Travel risk assessment, advice and vaccinations in immunocompromised travellers (HIV, solid organ) Tj ETQq1 1 Infectious Disease, 2015, 13, 31-47.	. 0.784314 1.5	rgBT /Overlo 38
144	Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. Journal of Antimicrobial Chemotherapy, 2015, 70, 1161-5.	1.3	26

#	Article	IF	Citations
145	The prevention and management of infections due to multidrug resistant organisms in haematology patients. British Journal of Clinical Pharmacology, 2015, 79, 195-207.	1.1	41
146	<i>Candida glabrata</i> fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. Leukemia and Lymphoma, 2015, 56, 3442-3444.	0.6	6
147	Nosocomial infections in the intensive care unit. Anaesthesia and Intensive Care Medicine, 2015, 16, 598-602.	0.1	34
148	A different kind of "allogeneic transplant― successful fecal microbiota transplant for recurrent and refractoryClostridium difficileinfection in a patient with relapsed aggressive B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 512-514.	0.6	14
149	An Approach to a Pulmonary Infiltrate in Solid Organ Transplant Recipients. Current Fungal Infection Reports, 2015, 9, 144-154.	0.9	2
150	Fusidic Acid., 2015,, 304-309.e2.		2
151	Taming the great: enhanced syphilis screening in HIV-positive men who have sex with men in a hospital clinic setting. Sexual Health, 2015, 12, 176.	0.4	7
152	An Unusual Pain in the Neck. Clinical Infectious Diseases, 2014, 58, 1638-1639.	2.9	1
153	An Unusual Pain in the Neck. Clinical Infectious Diseases, 2014, 58, 1577-1578.	2.9	0
154	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Internal Medicine Journal, 2014, 44, 1364-1388.	0.5	88
155	Disseminated <i>Scedosporium prolificans</i> infection in an â€extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. Mycoses, 2014, 57, 572-576.	1.8	23
156	Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer. Medical Mycology Case Reports, 2014, 6, 34-36.	0.7	4
157	Nonâ€ <scp>O</scp> 1, nonâ€ <scp>O</scp> 139 <scp><i>V</i></scp> <i>ii&gt;V<ii>ibrio cholerae</ii></i> acteraemia in an <scp>A</scp> ustralian population. Internal Medicine Journal, 2014, 44, 508-511.	0.5	26
158	The Incubation Period of Buruli Ulcer (Mycobacterium ulcerans Infection). PLoS Neglected Tropical Diseases, 2013, 7, e2463.	1.3	66
159	Faecal microbiota transplantation for severe clostridium difficile infection in the intensive care unit. European Journal of Gastroenterology and Hepatology, 2013, 25, 255-257.	0.8	63
160	Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to â€de-labeling'. Current Opinion in Infectious Diseases, 2013, 26, 526-537.	1.3	92
161	The look of leptospirosis in Victoria — recent trends. Medical Journal of Australia, 2013, 199, 465-465.	0.8	0
162	Bilateral thigh pain after treatment for prostate cancer. BMJ Case Reports, 2013, 2013, bcr2013008784-bcr2013008784.	0.2	6

#	Article	IF	CITATIONS
163	Coxiella burnetii endocarditis after Q fever vaccination. Journal of Medical Microbiology, 2012, 61, 1775-1779.	0.7	6